Archives: Search / 2023 / 2022 / 2021 / 2020 / 2019 / 2018 / 2017 / 2016 / 2015
2015 Archives
--Company Expects to Achieve Savings of $40 Million in the First 12 Months, More in Following Years-- Lannett Company, Inc. (NYSE: LCI) today announced that, following a review of its operations including the recently acquired Kremers Urban Pharmaceuticals Inc. (KU), it expects to achieve... More |
--Company to Discuss Integration Plans-- Lannett Company, Inc. (NYSE: LCI) today announced that it will host a special conference call on Monday, December 21, 2015 at 4:30 p.m. Eastern (1:30 p.m. Pacific) to discuss integration plans.... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Oppenheimer 26th Annual Healthcare Conference on Wednesday, December 9, 2015, at 10:20 a.m. ET at the Westin... More |
- Acquisition creates key player in generic drug industry Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the acquisition of Kremers Urban Pharmaceuticals Inc. (KU), the U.S. specialty generic pharmaceuticals subsidiary of global... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Jefferies Autumn 2015 Global Healthcare Conference on Wednesday, November 18, 2015, at 10 a.m. GMT. The... More |
--Net Sales of $106 Million, GAAP EPS OF $0.89, Adjusted EPS of $0.99-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2016 first quarter ended September 30, 2015. For the fiscal 2016 first quarter, net sales increased to $106.4... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2016 first quarter on Wednesday, November 4, 2015 after the market closes. Lannett management... More |
--Net Sales of Approximately $106 Million, GAAP EPS of $0.88 to $0.89, Adjusted EPS of $0.98 to $0.99-- Lannett Company, Inc. (NYSE: LCI) today announced that it expects to report fiscal 2016 first quarter net sales of approximately $106 million, GAAP earnings per diluted share of $0.88 to $0.89 and... More |
Lannett Company, Inc. (NYSE: LCI) today announced that its wholly owned subsidiary, Silarx Pharmaceuticals, Inc., has received approval from the U.S. Food and Drug Administration (FDA) of its... More |
Transaction Highlights: Substantially increases, diversifies revenue base with highly profitable specialty products Expands pipeline with exciting products Near-term growth potential with 11... More |
--Company Records Net Sales of $99 Million, EPS of $0.91; Provides Guidance for Fiscal 2016-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 fourth quarter and full year ended June 30, 2015. On June 1, 2015, the company completed the acquisition of... More |
Lannett Company, Inc. (NYSE: LCI) today announced that its Silarx Pharmaceuticals, Inc. subsidiary has received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2015 fourth quarter and full year on Tuesday, August 25, 2015 after the market closes.... More |
Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the Canaccord Genuity 35th Annual Growth Conference on Wednesday, August 12, 2015, at 2 p.m. Eastern at the... More |
Lannett Company, Inc. (NYSE: LCI) today announced that its Board of Directors has amended the corporation's bylaws to repeal Article XII in its entirety, effective July 31, 2015. By repealing... More |
Lannett Company, Inc. (NYSE: LCI) today announced the appointment of Albert R. Paonessa, III, to its Board of Directors, effective July 1, 2015. With the addition of Paonessa, the company's Board... More |
Jun 2, 2015 Lannett Company, Inc. (NYSE: LCI) today announced that it has completed the acquisition of privately held, Silarx Pharmaceuticals, Inc. and a related real estate entity (together "Silarx"), a... More |
May 18, 2015 Lannett Company, Inc. (NYSE: LCI) today announced that it has signed a definitive agreement to acquire privately held, Silarx Pharmaceuticals, Inc. and a related real estate entity (together... More |
--Company Records Net Sales of $99 Million, EPS of $0.97; Raises Guidance for Fiscal 2015-- Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 third quarter ended March 31, 2015. For the fiscal 2015 third quarter, net sales rose 24% to $99.4 million... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2015 third quarter on Wednesday, May 6, 2015 after the market closes. Lannett management will... More |
Lannett Company, Inc. (NYSE: LCI) today announced that it has amended and increased its five-year revolving credit facility to $120 million from $50 million. The amended facility includes an... More |
Philadelphia, PA – April 7, 2015 – Lannett Company, Inc. (NYSE: LCI) today announced that the company’s chief executive officer, Arthur Bedrosian, and chief financial officer, Martin... More |
Philadelphia, PA – February 27, 2015 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the 27th Annual ROTH Conference on Monday, March 9, 2015, at... More |
Philadelphia, PA – February 24, 2015 – Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the RBC Capital Markets 2015 Healthcare Conference today,... More |
Company Raises Outlook for Fiscal 2015 Philadelphia, PA – February 4, 2015 – Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2015 second quarter ended December 31, 2014. For the fiscal 2015... More |
| 1-25 26-27 |